P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial
Titel:
P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial
Auteur:
Shoji, H. Tsuda, T. Shimokawa, M. Akiyoshi, K. Tokunaga, S. Kunieda, K. Kotaka, M. Matsumoto, T. Nagata, Y. Mizukami, T. Mizuki, F. Danenberg, K. Sunakawa, Y. Boku, N. Nakajima, T.